CA2946032C - Utilisation d'analoge d'apc pour la cicatrisation des plaies - Google Patents
Utilisation d'analoge d'apc pour la cicatrisation des plaies Download PDFInfo
- Publication number
- CA2946032C CA2946032C CA2946032A CA2946032A CA2946032C CA 2946032 C CA2946032 C CA 2946032C CA 2946032 A CA2946032 A CA 2946032A CA 2946032 A CA2946032 A CA 2946032A CA 2946032 C CA2946032 C CA 2946032C
- Authority
- CA
- Canada
- Prior art keywords
- apc
- wound
- dermal
- repair
- wound healing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000029663 wound healing Effects 0.000 title abstract description 28
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 114
- 206010052428 Wound Diseases 0.000 claims abstract description 101
- 230000002500 effect on skin Effects 0.000 claims abstract description 51
- 230000001684 chronic effect Effects 0.000 claims abstract description 9
- 208000025865 Ulcer Diseases 0.000 claims abstract description 6
- 230000001154 acute effect Effects 0.000 claims abstract description 5
- 231100000397 ulcer Toxicity 0.000 claims abstract description 5
- 108700025721 3K3A-APC Proteins 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- 238000009472 formulation Methods 0.000 claims description 15
- 230000006907 apoptotic process Effects 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 9
- 239000002674 ointment Substances 0.000 claims description 8
- 230000008439 repair process Effects 0.000 claims description 6
- 239000007972 injectable composition Substances 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 208000034693 Laceration Diseases 0.000 claims description 4
- 238000005299 abrasion Methods 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000011200 topical administration Methods 0.000 claims description 3
- 230000037314 wound repair Effects 0.000 abstract description 34
- 238000000034 method Methods 0.000 abstract description 30
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 210000003491 skin Anatomy 0.000 description 21
- 230000006870 function Effects 0.000 description 17
- 230000006378 damage Effects 0.000 description 15
- 208000014674 injury Diseases 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 230000009885 systemic effect Effects 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 230000010100 anticoagulation Effects 0.000 description 7
- 230000001771 impaired effect Effects 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 208000037816 tissue injury Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000002424 anti-apoptotic effect Effects 0.000 description 5
- 239000006260 foam Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 101800004937 Protein C Proteins 0.000 description 4
- 101800001700 Saposin-D Proteins 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108010074105 Factor Va Proteins 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 102000017975 Protein C Human genes 0.000 description 3
- 102100037136 Proteinase-activated receptor 1 Human genes 0.000 description 3
- 101710121440 Proteinase-activated receptor 1 Proteins 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 229960004703 clobetasol propionate Drugs 0.000 description 3
- 230000001120 cytoprotective effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 229960000856 protein c Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 230000037390 scarring Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 208000035404 Autolysis Diseases 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 102000009839 Endothelial Protein C Receptor Human genes 0.000 description 2
- 108010009900 Endothelial Protein C Receptor Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 2
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 2
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 229940096422 collagen type i Drugs 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000008713 feedback mechanism Effects 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 208000036260 idiopathic disease Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000014508 negative regulation of coagulation Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001823 pruritic effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000036573 scar formation Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028043 self proteolysis Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 210000000438 stratum basale Anatomy 0.000 description 2
- 208000023516 stroke disease Diseases 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical class CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010054964 H-hexahydrotyrosyl-alanyl-arginine-4-nitroanilide Proteins 0.000 description 1
- 101500025568 Homo sapiens Saposin-D Proteins 0.000 description 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 108010049175 N-substituted Glycines Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- -1 NaCI Chemical compound 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101710186509 Partitioning defective 3 homolog Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000002020 Protease-activated receptors Human genes 0.000 description 1
- 108050009310 Protease-activated receptors Proteins 0.000 description 1
- 102100037133 Proteinase-activated receptor 3 Human genes 0.000 description 1
- 101710121425 Proteinase-activated receptor 3 Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 206010040893 Skin necrosis Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 125000003630 glycyl group Chemical class [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000037313 granulation tissue formation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229940100689 human protein c Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000029774 keratinocyte migration Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000020938 metabolic status Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- YEYHFKBVNARCNE-UHFFFAOYSA-N pyrido[2,3-b]pyrazine Chemical class N1=CC=NC2=CC=CN=C21 YEYHFKBVNARCNE-UHFFFAOYSA-N 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000037851 severe atopic dermatitis Diseases 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 210000000498 stratum granulosum Anatomy 0.000 description 1
- 210000000439 stratum lucidum Anatomy 0.000 description 1
- 210000000437 stratum spinosum Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000003041 virtual screening Methods 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4866—Protein C (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0076—Sprayable compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Materials Engineering (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente application concerne la réparation et la cicatrisation de plaies par l'application d'une quantité thérapeutique de protéine activée C-3K3A (APC-3K3A). Plus précisément, l'invention porte sur un procédé d'utilisation d'APC-3K3A pour le traitement des plaies dermiques ou cutanées, y compris, mais pas exclusivement, les blessures aiguës et chroniques, les brûlures et les ulcères.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014901397 | 2014-04-16 | ||
| AU2014901397A AU2014901397A0 (en) | 2014-04-16 | Treatment of abnormal cutaneous scarring | |
| AU2014902900 | 2014-07-25 | ||
| AU2014902900A AU2014902900A0 (en) | 2014-07-25 | Use of APC analogue for wound healing | |
| PCT/AU2015/050177 WO2015157822A1 (fr) | 2014-04-16 | 2015-04-16 | Utilisation d'analoge d'apc pour la cicatrisation des plaies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2946032A1 CA2946032A1 (fr) | 2015-10-22 |
| CA2946032C true CA2946032C (fr) | 2022-06-14 |
Family
ID=54323284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2946032A Active CA2946032C (fr) | 2014-04-16 | 2015-04-16 | Utilisation d'analoge d'apc pour la cicatrisation des plaies |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20170035862A1 (fr) |
| EP (1) | EP3131572B1 (fr) |
| JP (2) | JP6873387B2 (fr) |
| CN (1) | CN106488773B (fr) |
| AU (1) | AU2015246656B2 (fr) |
| CA (1) | CA2946032C (fr) |
| DK (1) | DK3131572T3 (fr) |
| ES (1) | ES2890623T3 (fr) |
| PL (1) | PL3131572T3 (fr) |
| PT (1) | PT3131572T (fr) |
| WO (1) | WO2015157822A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014005183A1 (fr) | 2012-07-04 | 2014-01-09 | The University Of Sydney | Traitement de troubles cutanés inflammatoires |
| ES2890675T3 (es) | 2014-04-16 | 2022-01-21 | Zz Biotech Llc | APC para uso en el tratamiento de cicatrices cutáneas anormales |
| CN107619437B (zh) * | 2017-11-07 | 2019-08-13 | 昆明医科大学 | 一种皮肤创伤修复肽whpp-oa1及其提纯方法与应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4775624A (en) | 1985-02-08 | 1988-10-04 | Eli Lilly And Company | Vectors and compounds for expression of human protein C |
| US4959318A (en) | 1985-06-27 | 1990-09-25 | Zymogenetics, Inc. | Expression of protein C |
| US5516650A (en) | 1985-06-27 | 1996-05-14 | Zymogenetics, Inc. | Production of activated protein C |
| WO1989012685A1 (fr) | 1987-05-18 | 1989-12-28 | Integrated Genetics, Inc. | Molecules de proteine c ameliorees et procede de production et d'activation de telles molecules |
| US5084274A (en) | 1987-11-17 | 1992-01-28 | Scripps Clinic And Research Foundation | Inhibition of arterial thrombotic occlusion or thromboembolism |
| US4981952A (en) | 1988-10-04 | 1991-01-01 | Eli Lilly And Company | Method for the purification of vitamin K-dependent proteins |
| US5093117A (en) | 1989-01-24 | 1992-03-03 | Baxter International Inc. | Compositions and method for the treatment or prophylaxis of sepsis or septic shock |
| AT402260B (de) | 1990-08-16 | 1997-03-25 | Immuno Ag | Protein c-hältige pharmazeutische präparation |
| US5571786A (en) | 1990-08-16 | 1996-11-05 | Immuno Aktiengesellschaft | Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation |
| AT397615B (de) | 1991-05-14 | 1994-05-25 | Immuno Ag | Arzneimittel enthaltend protein c |
| WO1993009807A1 (fr) | 1991-11-18 | 1993-05-27 | The Scripps Research Institute | Procedes d'inhibition de la thrombose par elevation des taux de proteine c activee endogene dans la circulation |
| MY110664A (en) | 1992-05-21 | 1999-01-30 | Lilly Co Eli | Protein c derivatives |
| DE4239150A1 (de) | 1992-11-20 | 1994-05-26 | Thomae Gmbh Dr K | O-Acyl-4-phenyl-cyclohexanole, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung |
| JP3043558B2 (ja) | 1993-10-29 | 2000-05-22 | 財団法人化学及血清療法研究所 | ヒト活性化プロテインｃ調製物及びその製法 |
| WO1995030429A1 (fr) | 1994-05-04 | 1995-11-16 | Board Of Trustees Of The University Of Arkansas | Nouvelles utilisations ophtalmologiques de la proteine c |
| US6162629A (en) | 1997-04-28 | 2000-12-19 | Eli Lilly And Company | Methods for processing activated protein C |
| HUP0001237A3 (en) | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
| US7074402B2 (en) | 2000-02-04 | 2006-07-11 | The Scripps Research Institute | Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein C (APC) |
| JP2003521938A (ja) | 2000-02-11 | 2003-07-22 | イーライ・リリー・アンド・カンパニー | プロテインｃ誘導体 |
| ATE298246T1 (de) | 2000-03-28 | 2005-07-15 | Lilly Co Eli | Aktiviertes protein c zur behandlung von pankreatitis |
| WO2002032461A2 (fr) | 2000-10-18 | 2002-04-25 | Maxygen Aps | Molecules de proteine c ou de type proteine c activee |
| EP1404412B1 (fr) * | 2001-06-13 | 2012-03-21 | The University of Sydney | Protéine C pour la cicatrisation des plaies |
| AU2003275948A1 (en) | 2002-11-06 | 2004-06-07 | Novo Nordisk A/S | Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides |
| ES2269858T3 (es) | 2003-04-28 | 2007-04-01 | Biofrontera Bioscience Gmbh | Utilizacion de riluzol combinado con sustancias auxiliares y aditivos adecuados pra el tratamiento de enfermedades, caracterizadas una hiperproliferacion de queratinocitos, en particular neurodermitis y psoriasis. |
| WO2005007820A2 (fr) * | 2003-07-08 | 2005-01-27 | The Scripps Research Institute | Variants de proteine c activee avec activite cytoprotectrice normale mais avec activite anticoagulante reduite |
| US9192657B2 (en) | 2003-07-08 | 2015-11-24 | The Scripps Research Institute | Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity |
| US20070224150A1 (en) | 2005-03-24 | 2007-09-27 | Yongji Chung | Growth factor for hair and skin treatment |
| DK1896059T3 (da) | 2005-06-24 | 2013-04-08 | Drugrecure Aps | Luftvejsadministration af Tissue Factor Pathway Inhibitor ved inflammatoriske tilstande, der påvirker luftvejene |
| GR1005700B (el) | 2006-09-01 | 2007-10-22 | (40%) ����� �������� | Τροπος αντιμετωπισης της 1ης φασης του εγκαυματοσσε μη σηπτικους ασθενεις με συνεχη ενδοφλεβια χορηγηση ενεργοποιημενης πρωτεινης-c για 48 ωρες με στοχο τη μειωση της τελικης εγκαυματικης βλαβης καιαυξηση της ταχυτητας επουλωσης κατα τα πρωτα επτα μετεγκαυματικα 24ωρα |
| EP2078074A4 (fr) * | 2006-10-31 | 2011-09-28 | Scripps Research Inst | Schéma posologique de protéine c activée et de ses variants présentant une activité anticoagulante réduite |
| GB0724231D0 (en) | 2007-12-12 | 2008-01-30 | Renono Ltd | Methods for inhibiting scarring |
| ES2316312B1 (es) | 2008-06-20 | 2010-02-08 | Ignacio Umbert Millet | Composicion farmaceutica dermatologica para el tratamiento de patologias de inflamacion de la piel, tales como por ejemplo dermatitis, dermatitis atopica, vitiligo, alopecia areata, acne, psoriasis y prurito,y combinaciones de las mismas. |
| EP2157176A1 (fr) | 2008-08-20 | 2010-02-24 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Variantes de la protéine C |
| CN101912450A (zh) | 2010-09-01 | 2010-12-15 | 吴业刚 | 一种治疗脚气皮炎的中西药组合物及其制备方法 |
| WO2014005183A1 (fr) * | 2012-07-04 | 2014-01-09 | The University Of Sydney | Traitement de troubles cutanés inflammatoires |
| ES2890675T3 (es) | 2014-04-16 | 2022-01-21 | Zz Biotech Llc | APC para uso en el tratamiento de cicatrices cutáneas anormales |
-
2015
- 2015-04-16 AU AU2015246656A patent/AU2015246656B2/en active Active
- 2015-04-16 PL PL15779573T patent/PL3131572T3/pl unknown
- 2015-04-16 ES ES15779573T patent/ES2890623T3/es active Active
- 2015-04-16 WO PCT/AU2015/050177 patent/WO2015157822A1/fr not_active Ceased
- 2015-04-16 PT PT157795733T patent/PT3131572T/pt unknown
- 2015-04-16 CN CN201580025422.7A patent/CN106488773B/zh active Active
- 2015-04-16 EP EP15779573.3A patent/EP3131572B1/fr active Active
- 2015-04-16 DK DK15779573.3T patent/DK3131572T3/da active
- 2015-04-16 CA CA2946032A patent/CA2946032C/fr active Active
- 2015-04-16 JP JP2017505687A patent/JP6873387B2/ja active Active
- 2015-04-16 US US15/304,433 patent/US20170035862A1/en not_active Abandoned
-
2018
- 2018-02-15 US US15/897,801 patent/US20180243383A1/en not_active Abandoned
-
2019
- 2019-09-13 US US16/569,975 patent/US12214024B2/en active Active
-
2020
- 2020-02-27 JP JP2020031999A patent/JP2020100648A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015246656A1 (en) | 2016-11-03 |
| DK3131572T3 (da) | 2021-10-11 |
| US12214024B2 (en) | 2025-02-04 |
| JP6873387B2 (ja) | 2021-05-19 |
| JP2017513945A (ja) | 2017-06-01 |
| PL3131572T3 (pl) | 2022-02-07 |
| EP3131572B1 (fr) | 2021-07-14 |
| CA2946032A1 (fr) | 2015-10-22 |
| ES2890623T3 (es) | 2022-01-20 |
| US20200000890A1 (en) | 2020-01-02 |
| US20170035862A1 (en) | 2017-02-09 |
| JP2020100648A (ja) | 2020-07-02 |
| EP3131572A1 (fr) | 2017-02-22 |
| CN106488773B (zh) | 2020-02-11 |
| AU2015246656B2 (en) | 2020-06-18 |
| PT3131572T (pt) | 2021-09-24 |
| EP3131572A4 (fr) | 2017-12-20 |
| WO2015157822A1 (fr) | 2015-10-22 |
| CN106488773A (zh) | 2017-03-08 |
| US20180243383A1 (en) | 2018-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Long et al. | Controlled delivery of platelet-derived proteins enhances porcine wound healing | |
| US11491214B2 (en) | Treatment of abnormal cutaneous scarring | |
| US20160058834A1 (en) | Formulations and methods of use for alpha connexin c-terminal (act) peptides | |
| US12214024B2 (en) | Use of APC analogue for wound healing | |
| KR20080031405A (ko) | 상피 재생의 촉진 | |
| CN100509055C (zh) | 使用凝血酶衍生的缩氨酸治疗慢性真皮溃疡 | |
| AU2019343514B2 (en) | Agent for treatment of dermatological disorders | |
| HK1230520A1 (en) | Use of apc analogue for wound healing | |
| HK1230520B (zh) | Apc类似物用於创伤癒合的用途 | |
| HK40047629A (zh) | 皮肤病治疗剂 | |
| HK1235306B (zh) | 治疗异常皮肤瘢痕形成 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200130 |
|
| EEER | Examination request |
Effective date: 20200130 |